Previous 10 | Next 10 |
2023-05-11 17:35:17 ET Delcath Systems ( NASDAQ: DCTH ) is scheduled to announce Q1 earnings results on Friday, May 12th, after market close. The consensus EPS Estimate is -$0.58 (+42.0% Y/Y) and the consensus Revenue Estimate is $0.79M (+107.9% Y/Y). Over the last 1 y...
Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference PR Newswire NEW YORK , May 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ca...
Delcath Systems to Host First Quarter 2023 Results PR Newswire NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today...
Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility PR Newswire Amendment with Avenue Venture Opportunities Fund, L.P. provides for an interest-only period from March 31, 2023 to September 30, 2023 and defers $4.3 million in pri...
Delcath Systems Announces Closing of Private Placement of up to $85 Million PR Newswire Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors ...
2023-03-27 09:19:20 ET Delcath Systems press release ( NASDAQ: DCTH ): Q4 GAAP EPS of -$0.86 misses by $0.10 . Revenue of $0.64M (+156.0% Y/Y) misses by $0.2M . On December 31, 2022, the Company had cash, cash equivalents and restricted cash totaling $11.8 mill...
2023-03-27 08:53:45 ET Oncology-focused healthcare equipment maker Delcath Systems ( NASDAQ: DCTH ) announced Monday that the FDA accepted its resubmitted new drug application (NDA) for the HEPZATO Kit for certain liver-dominant eye cancer. The FDA has issued August 14, 20...
2023-03-27 08:23:17 ET Delcath Systems ( NASDAQ: DCTH ) announced that it has signed securities purchase agreements with certain healthcare-focused institutional investors that will provide up to $85M in gross proceeds through a private placement that includes initial upf...
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update PR Newswire NEW YORK , March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and m...
Delcath Systems Announces up to $85 Million Financing PR Newswire Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million fi...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...